Aptamer Sciences' Trop2‑ApDC chosen for national new drug project, boosting global tech transfer

Aptamer Sciences announced that its Trop2‑ApDC candidate has been selected for a national new drug development project. The selection is part of a program aimed at advancing innovative therapeutics. Inclusion in the project is expected to accelerate global technology transfer. The announcement was reported by 아시아경제. The candidate, known as Trop2‑ApDC, is part of the company's pipeline. The project will provide funding and development support. The move highlights the company's role in drug discovery. Stakeholders will watch for progress as the candidate moves forward.